Most Read Articles
Pearl Toh, 3 days ago
Not only does the CGRP* inhibitor galcanezumab show sustained efficacy in migraine patients, long-term treatment does not come with excess cardiovascular (CV) risk, according to studies presented at the AAN 2021 Annual Meeting.
01 Apr 2021
Migraine and headache are common ailments of people living in the modern era. Dr Jon Marshall of The Singapore Headache and Migraine Clinic shares his insights with Pearl Toh on how to manage migraine and headache using non-pharmaceutical strategies, with a focus on the manual medicine approach.
Tristan Manalac, 5 days ago
Visceral fat area is the strongest indicator of mobility disability among obese, community-dwelling, older adults, according to a recent Singapore study.
3 days ago
In a webinar held on 27 March 2021, paediatric endocrinology nurses Karen Blair, Kate Davies, and Siti Zarina Yaakop shared insights and clinical experience based on their frontline roles in caring for patients with central precocious puberty (CPP) and supporting their family members.

COVID-19 vaccines safe, effective in NAFLD patients

02 May 2021

Vaccination against SARS-CoV-2 does not seem to come with significant safety concerns in patients with nonalcoholic fatty liver disease (NAFLD), a recent study has found. At the same time, vaccines can also elicit a robust neutralizing antibody response.

The study included 381 NAFLD patients (median age 39.0 years, 47.0 percent men) who had never had the novel coronavirus disease (COVID-19). All participants had received two doses of an inactivated virus vaccine, 14 days after which blood samples were collected. Neutralizing antibodies were detected using magnetic particle chemiluminescence assays. The primary safety outcome of interest was the occurrence of adverse events within 7 days after each injection.

Overall, 95 patients saw adverse reactions within 7 days after each injection, while 112 patients had adverse reactions within 28 days. The most common side effects were injection site pain (n=70; 18.4 percent), muscle pain (n=21; 5.5 percent), headache (n=20; 5.2 percent), and fatigue (n=18; 4.7 percent).

All adverse events were mild and self-limiting; there were no grade 3 reactions recorded.

In terms of immunogenicity, neutralizing antibodies were first detected after a median of 39.0 days. Almost all (95.5 percent; n=364) of the patients vaccinated showed neutralizing antibodies, with a median titre of 32.

“A larger prospective follow-up study for robust evidence of efficacy (ie, protection against severe disease and death) is needed,” the researchers said. “In conclusion, the inactivated COVID-19 vaccine appears to be safe with good immunogenicity in patients with NAFLD.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
Not only does the CGRP* inhibitor galcanezumab show sustained efficacy in migraine patients, long-term treatment does not come with excess cardiovascular (CV) risk, according to studies presented at the AAN 2021 Annual Meeting.
01 Apr 2021
Migraine and headache are common ailments of people living in the modern era. Dr Jon Marshall of The Singapore Headache and Migraine Clinic shares his insights with Pearl Toh on how to manage migraine and headache using non-pharmaceutical strategies, with a focus on the manual medicine approach.
Tristan Manalac, 5 days ago
Visceral fat area is the strongest indicator of mobility disability among obese, community-dwelling, older adults, according to a recent Singapore study.
3 days ago
In a webinar held on 27 March 2021, paediatric endocrinology nurses Karen Blair, Kate Davies, and Siti Zarina Yaakop shared insights and clinical experience based on their frontline roles in caring for patients with central precocious puberty (CPP) and supporting their family members.